PHAT
insider transactionsPhathom Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·G
Director
$0
28.0K sh
Own -54%
-
Other·D
Director
$0
17.5K sh
Own -100%
-
Exercise·M
Director
$86.6K
17.5K sh · $4.95
Own +51%
-
Grant·A
Director, 10% Owner
$0
24.1K sh
Own +57%
-
Grant·A
Director
$0
24.1K sh
Own +80%
-
Grant·A
Director
$0
24.1K sh
Own +115%
-
Grant·A
Director
$0
24.1K sh
Own +230%
-
Grant·A
Director
$0
24.1K sh
Own +36%
-
Grant·A
Director
$0
24.1K sh
Own +80%
-
Grant·A
Director
$0
24.1K sh
Own +61%
-
Other·G
Director
$0
40.0K sh
Own -79%
-
Other·F
Principal Accounting Officer
$5.2K
414 sh · $12.56
Own -1%
-
Other·F
Principal Accounting Officer
$12.1K
964 sh · $12.56
Own -2%
-
Grant·A
Principal Accounting Officer
$0
2.8K sh
Own +5%
-
Grant·A
Principal Accounting Officer
$0
13.0K sh
Own +28%
-
Other·F
Chief Legal Off. & Corp. Sec.
$19.7K
1.5K sh · $12.82
Own -2%
-
Grant·A
Chief Legal Off. & Corp. Sec.
$0
3.5K sh
Own +4%
-
Other·F
Steven L Basta KEY
President and CEO
$80.5K
6.3K sh · $12.82
Own -2%
-
Grant·A
Steven L Basta KEY
President and CEO
$0
12.4K sh
Own +3%
-
Other·G
Director
$0
80.5K sh
Own -61%
-
Other·F
Principal Accounting Officer
$10.6K
776 sh · $13.61
Own -2%
-
Exercise·M
Director
$0
8.8K sh
Own New
-
Exercise·M
Director
$90.1K
8.8K sh · $10.30
Own +7%
-
Grant·A
Sanjeev Narula KEY
Chief Financial & Bus. Officer
$0
42.8K sh
Own New
-
Grant·A
Sanjeev Narula KEY
Chief Financial & Bus. Officer
$0
82.7K sh
Own +57%
-
Grant·A
Chief Legal Off. & Corp. Sec.
$0
67.9K sh
Own New
-
Grant·A
Chief Legal Off. & Corp. Sec.
$0
75.3K sh
Own +779%
-
Grant·A
Steven L Basta KEY
President and CEO
$0
226.2K sh
Own New
-
Grant·A
Steven L Basta KEY
President and CEO
$0
251.0K sh
Own +221%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Asit Parikh | Other G | 28.0K | $0 |
| May 20, 2026 | Asit Parikh | Other D | 17.5K | $0 |
| May 20, 2026 | Asit Parikh | Exercise M | 17.5K | $86.6K |
| May 19, 2026 | James N Topper | Grant A | 24.1K | $0 |
| May 19, 2026 | Mark Stenhouse | Grant A | 24.1K | $0 |
| May 19, 2026 | Theodore R Schroeder | Grant A | 24.1K | $0 |
| May 19, 2026 | Asit Parikh | Grant A | 24.1K | $0 |
| May 19, 2026 | Frank Karbe | Grant A | 24.1K | $0 |
| May 19, 2026 | Heidi Fields | Grant A | 24.1K | $0 |
| May 19, 2026 | Michael F Cola | Grant A | 24.1K | $0 |
| Mar 10, 2026 | Asit Parikh | Other G | 40.0K | $0 |
| Feb 27, 2026 | Robert Charles Breedlove | Other F | 414 | $5.2K |
| Feb 27, 2026 | Robert Charles Breedlove | Other F | 964 | $12.1K |
| Feb 27, 2026 | Robert Charles Breedlove | Grant A | 2.8K | $0 |
| Feb 27, 2026 | Robert Charles Breedlove | Grant A | 13.0K | $0 |
| Feb 10, 2026 | Anne Marie Cook | Other F | 1.5K | $19.7K |
| Feb 10, 2026 | Anne Marie Cook | Grant A | 3.5K | $0 |
| Feb 10, 2026 | Steven L Basta KEY | Other F | 6.3K | $80.5K |
| Feb 10, 2026 | Steven L Basta KEY | Grant A | 12.4K | $0 |
| Jan 23, 2026 | Asit Parikh | Other G | 80.5K | $0 |
| Jan 21, 2026 | Robert Charles Breedlove | Other F | 776 | $10.6K |
| Jan 13, 2026 | Asit Parikh | Exercise M | 8.8K | $0 |
| Jan 13, 2026 | Asit Parikh | Exercise M | 8.8K | $90.1K |
| Jan 2, 2026 | Sanjeev Narula KEY | Grant A | 42.8K | $0 |
| Jan 2, 2026 | Sanjeev Narula KEY | Grant A | 82.7K | $0 |
| Jan 2, 2026 | Anne Marie Cook | Grant A | 67.9K | $0 |
| Jan 2, 2026 | Anne Marie Cook | Grant A | 75.3K | $0 |
| Jan 2, 2026 | Steven L Basta KEY | Grant A | 226.2K | $0 |
| Jan 2, 2026 | Steven L Basta KEY | Grant A | 251.0K | $0 |
About PHAT insider trading
This page tracks insider transactions for Phathom Pharmaceuticals, Inc. (PHAT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.